

Jan-04-05 04:25pm From-Cooper&Dunham LLP

+212 391 0526

T-702 P.001/014 F-087

RECEIVED
CENTRAL FAX CENTER

COOPER & DUNHAM LLP
ATTORNEYS AT LAW
1185 AVENUE OF THE AMERICAS, NEW YORK, NEW YORK 10036
TELEPHONE: (212) 278-0400

JAN 04 2005

FACSIMILE: (212) 391-0525
(312) 391-0526
(212) 391-0630

OF COUNSEL
DONALD E. DOWDEN

SCIENTIFIC ADVISOR
MURIEL M. LIBERTO, PH.D.

FOUNDED 1887
www.cooperdunham.com

CHRISTOPHER C. DUNHAM
NORMAN H. ZIVIN
JOHN P. WHITE
WILLIAM C. PELOTON
ROBERT G. KATZ
DONNA A. TOBIN
RICHARD S. MILNER
RICHARD F. JAWORSKI
PAUL TENG
GARY J. GERSHIN
JASON S. MARIN
MARIA V. MARUCCI
ARIAN A. BARTALAI
ASHTON J. DELAUNEY
CINDY YANG
BRIAN J. AMOS
JOSEPH B. CROSS
DANIEL R. SMITH*

IVAN S. KAVRUVOV
PETER D. MURRAY
JAY H. MAJOLI
ROBERT B.G. MOROWITZ
PETER J. PHILLIPS
WENDY E. MILLER
ROBERT T. MALDONADO
ERIC D. KIRSCH
ALAN J. MORRISON
PEDRO C. FERNANDEZ
KEITH J. BARNHAUS
ANTHONY V. FLINT
AUDE GERSPACHER
JEFFREY C. SHIEH
NAresh BHATHARAN
DAVID J. KERWICK*
TONIA A. SAYOUR

FACSIMILE TRANSMISSION

* NEW YORK STATE BAR ADMISSION PENDING

PLEASE DELIVER THE FOLLOWING PAGES

TO: USPTO CENTRAL FACSIMILE NUMBER

COMPANY/FIRM: U.S. Patent and Trademark Office

FACSIMILE NO.: (703) 872-9306

FROM: John P. White, Esq./AJD

TOTAL NUMBER OF PAGES, INCLUDING COVER PAGE: 14

DATE: January 4, 2005 TIME:

SERIAL NO.: 09/891,062, filed June 25, 2001 (Our Docket
48965-B/JFW/AJD)

RE: Communication Regarding December 7, 2004 Examiner's Interview in connection with Virginia M. Litwin et al., COMPOUNDS CAPABLE OF INHIBITING HIV-1 INFECTION, U.S. Serial No. 08/891,062, filed June 25, 2001, including a signed Facsimile Certificate of Mailing dated January 4, 2005.

IF YOU DO NOT RECEIVE ALL THE PAGES, PLEASE CALL BACK AS SOON AS POSSIBLE TO (212) 278-0400.

THE INFORMATION CONTAINED IN THIS FACSIMILE TRANSMISSION IS INTENDED SOLELY FOR THE PERSONAL AND CONFIDENTIAL USE OF THE DESIGNATED RECIPIENT(S) NAMED ABOVE. THIS TRANSMISSION MAY BE AN ATTORNEY-CLIENT COMMUNICATION CONTAINING INFORMATION THAT IS PRIVILEGED AND CONFIDENTIAL. IF THE READER OF THIS MESSAGE IS NOT A DESIGNATED RECIPIENT OR AN AGENT RESPONSIBLE FOR DELIVERING IT TO A DESIGNATED RECIPIENT, YOU ARE HEREBY NOTIFIED THAT YOU HAVE RECEIVED THIS DOCUMENT IN ERROR, AND THAT ANY REVIEW, DISTRIBUTION, OR COPYING OF THIS MESSAGE IS STRICTLY PROHIBITED. IF YOU HAVE RECEIVED THIS COMMUNICATION IN ERROR, OR IF UPON READING THIS DOCUMENT YOU HAVE REASON TO BELIEVE THAT THE DOCUMENT WAS INADVERTENTLY SENT TO YOU, PLEASE NOTIFY US IMMEDIATELY BY COLLECT TELEPHONE CALL AND RETURN THE ORIGINAL MESSAGE TO US BY MAIL. THANK YOU.

JAN 04 2005

Docket No. 48965-B/JPW/AJD

IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

Applicants: Virginia M. Litwin et al.

Serial No.: 09/891,062 Examiner: Jeffrey S. Parkin

Filed: June 25, 2001 Group Art Unit: 1648

For: COMPOUNDS CAPABLE OF INHIBITING HIV-1 INFECTION

1185 Avenue of the Americas
New York, New York 10036
January 4, 2005

Commissioner for Patents
P.O. Box 1450
Alexandria, VA 22313-1450

Sir:

COMMUNICATION REGARDING DECEMBER 7, 2004 EXAMINER'S INTERVIEW

This Communication is submitted pursuant to 37 C.F.R. 1.133(b) to make of record the substance of the discussion between Examiner Jeffrey S. Parkin and applicants during an interview held December 7, 2004 at the U.S. Patent and Trademark Office in connection with the above-identified application. In attendance at the December 7, 2004 interview were Examiner Jeffrey S. Parkin, Dr. Paul J. Maddon (one of the named inventors and Chief Executive Officer of the assignee of record, Progenics Pharmaceuticals, Inc., ("Progenics")), Dr. William C. Olson and Dr. Kathryn M. Brown of Progenics, Ashton J. Delauney, Esq., an associate in the undersigned's law firm, and the undersigned.

The Examiner provided to applicants a written Interview Summary (Form PTOL-413) at the completion of the interview, and a copy thereof was mailed to applicants on December 9, 2004. The present Communication is intended to provide further details of applicants' discussion with the Examiner and thereby complete the record concerning the issues discussed.

Before summarizing the interview, applicants wish to thank Examiner Parkin for the courtesy extended in the interview held December 7, 2004. Applicants understand that the interview was

Applicants: Virginia M. Litwin et al.
Serial No.: 09/891,062
Filed: June 25, 2001
Page 2

very helpful to the Examiner and are optimistic that the subject application can now be allowed.

Introductory Statements

Applicants' undersigned representative noted that five applications were scheduled for discussion: U.S. Serial Nos. 09/904,356, filed July 12, 2001; 09/460,216, filed December 13, 1999; 09/891,062, filed June 25, 2001; 09/412,284, filed October 5, 1999; and 10/116,797, filed April 5, 2002. Prior to specifically discussing any of these five applications, applicants presented introductory remarks on the scientific background and legal concepts common to all the applications in order to provide an appropriate context for the subsequent discussion of the individual applications.

Overview of Scientific Background

Applicant Dr. Paul J. Madden then presented an overview of the scientific background concerning the infection process by human immunodeficiency virus (HIV-1) and applicant's role in research thereon. Applicant noted that the HIV-1 infection process occurs in three stages: 1) attachment of HIV-1 through the envelope glycoprotein gp120 to a CD4 receptor on the target cell membrane; 2) fusion of the HIV-1 and target cell membranes after binding to a second receptor (CCR5); and 3) entry of viral DNA into a susceptible target cell mediated by the HIV-1 envelope glycoprotein gp41. Applicant stated that his and his group's contributions to this area of research involved, inter alia, the initial cloning of the CD4 gene in the early 1990's; identification of CD4 as the site of attachment for gp120; characterization of the functional distinction between macrophage-tropic and T cell-tropic strains of HIV-1 based on their differential binding to CD4⁺ cells; identification of CCR5

Applicants: Virginia M. Litwin et al.
Serial No.: 09/891,062
Filed: June 25, 2001
Page 3

as the second cell surface receptor mediating fusion of HIV-1 to target cells; and development of a resonance energy transfer (RET) assay to study the process of fusion of macrophage-tropic HIV-1 strains to target cell membranes. It was noted that Progenics was founded, in part, to identify inhibitors of these three stages of HIV-1 infection and to develop such inhibitors as anti-HIV-1 therapeutics. Applicant emphasized the novelty of this therapeutic approach by noting that out of 20 anti-HIV drugs currently on the market, all but one target viral enzymes, e.g., reverse transcriptase and protease, the exception being (Fuzeon®; T-20) which targets viral fusion.

Overview of Legal Concepts

Applicants' undersigned representative then summarized the legal concepts applicable to the cases to be discussed.

Absence of Prior Art

The undersigned noted that because of applicants' pioneering role in the scientific research on which the instant applications were based, there was no prior art being cited in connection with any of the five applications to be discussed. The undersigned also noted that as a consequence of filing early-stage applications soon after making scientific breakthroughs, certain applications may not have had a large number of experimental examples of the inventions, and this was a factor which would be further considered in regard to the outstanding written description and enablement rejections in certain of the applications. The Examiner acknowledged that prior art was not an issue with respect to the five applications to be discussed.

Applicants: Virginia M. Litwin et al.
Serial No.: 09/891,062
Filed: June 25, 2001
Page 4

Legal Standard for Enablement Rejections

The undersigned noted that the Examiner had issued rejections for an alleged lack of enablement in several of the applications. The undersigned also noted that the leading case on enablement, *In re Wands*, 8 U.S.P.Q.2d 1400 (Fed. Cir. 1988), emphasized that the legal standard for lack of enablement is a requirement for undue experimentation, i.e., experimentation that is not routine.

In this context, the amount of experimentation required to practice the invention is irrelevant, the critical question being whether the experimentation required is routine. See *In re Wands*, 8 USPQ2d 1400, 1404:

"Enablement is not precluded by the necessity for some experimentation such as routine screening. However, experimentation needed to practice the invention must not be undue experimentation. ... The test is not merely quantitative, since a considerable amount of experimentation is permissible, if it is merely routine, or if the specification in question provides a reasonable amount of guidance with respect to the direction in which experimentation should proceed. (citations omitted)

The undersigned noted that *Wands* is a case involving the making of monoclonal antibodies, in which the Federal Circuit reversed an Examiner's initial non-enablement rejection that had been sustained by the Board of Patent Appeals and Interferences on the basis that, whereas considerable experimentation was required, this experimentation involved routine screening of hybridoma cell lines and hence was not undue experimentation.

The undersigned noted that the RET assay developed by applicants for identifying agents that inhibit fusion of HIV-1 to target cells is highly predictive for agents having the property of inhibiting HIV-1 fusion, and undue experimentation is not required to so identify said agents.

The undersigned acknowledged that not all agents so identified

Applicants: Virginia M. Litwin et al.
Serial No.: 09/891,062
Filed: June 25, 2001
Page 5

would become drugs useful in treating humans because of considerations such as toxicity and undesirable side effects. The undersigned emphasized, however, that such considerations are irrelevant to patentability and instead are the concern of the Food and Drug Administration (citing *Scott v. Finney* 32 U.S.P.Q. 2d 1115, 1120 (Fed. Cir. 1994)).

Testing for the full safety and effectiveness of a prosthetic device is more properly left to the Food and Drug Administration (FDA) ... Congress has given the responsibility to the FDA, not to the [PTO], to determine ... whether drugs are sufficiently safe ... (citations omitted)

In addition, the undersigned reminded the Examiner that "it is not necessary that a court review all of the Wands factors to find a disclosure enabling. They are illustrative, not mandatory. What is relevant depends on the facts ..." *Amgen v. Chugai Pharmaceutical* 927 F.2d 1200, 1213 (Fed. Cir. 1991). The undersigned stated that he hoped to persuade the Examiner that a sufficient number of the Wands factors had been satisfied to establish that the specification was enabling for the inventions being claimed.

The undersigned also noted that as part of the enablement rejections, the Examiner had stated that use of the RET assay to identify fusion inhibitors does not constitute rational drug design. The undersigned agreed, noting that in the pharmaceutical industry, "rational drug design" is not the norm. Instead, the historical norm for identifying new candidate drugs is screening of large numbers of compounds. The undersigned noted that, in fact, it is only within the past ten years or so that Agouron Pharmaceuticals, Inc. (now part of Pfizer, Inc.) had successfully developed and marketed the first drug based on rational drug design.

The undersigned also noted that the Examiner had sometimes cited

Applicants: Virginia M. Litwin et al.
Serial No.: 09/891,062
Filed: June 25, 2001
Page 6

in his enablement rejections a lack of disclosure about the mechanism of action of a drug. The undersigned asserted, however, that disclosure of a mechanism is not a requirement for patentability. In response, the Examiner commented that it helps if the mechanism is disclosed, but acknowledged that disclosure of a mechanism is not required.

The undersigned also pointed to the fact that a single example of an embodiment of the invention may suffice to show enablement provided that "any gaps between the disclosures and the claim breadth could be easily bridged." *Amgen v. Hoechst* 314 F.3d 1313, 1336 (Fed. Cir. 2003). In this context, the undersigned stated that the instant applications and expert declarations previously submitted provide many examples of HIV-1 fusion inhibitors including chemokines, antibodies, and small molecules.

Examiner Must Consider Expert Declarations

The undersigned noted that in three of the applications under consideration, expert declarations had been submitted to support applicants' arguments in response to written description and enablement rejections, two each in two applications and one in the third. The undersigned emphasized that the Examiner is required to consider and give weight to these expert declarations, and if the statements therein are rejected, specific reasons have to be provided by the Examiner for rejecting them (citing M.P.E.P. §2164.05 and *In re Alton*).

Applicant may submit factual affidavits under 37 CFR 1.132 or cite references to show what one skilled in the art knew at the time of filing the application. A declaration or affidavit is, itself, evidence that must be considered. The weight to give a declaration or affidavit will depend upon the amount of factual evidence the declaration or affidavit contains to support the conclusion of enablement. *In re Buchner*, 929 F.2d 660, 661, 18 USPQ2d 1331, 1332 (Fed. Cir. 1991) ("expert's opinion on the ultimate legal conclusion must be supported by something more than a

Applicants: Virginia M. Litwin et al.
Serial No.: 09/891,062
Filed: June 25, 2001
Page 7

conclusory statement"); cf. *In re Alton*, 76 F.3d 1168, 1174, 37 USPQ2d 1578, 1583 (Fed. Cir. 1996) (declarations relating to the written description requirement should have been considered)...

The examiner must then weigh all the evidence before him or her, including the specification and any new evidence supplied by applicant with the evidence and/or sound scientific reasoning previously presented in the rejection and decide whether the claimed invention is enabled. The examiner should never make the determination based on personal opinion. The determination should always be based on the weight of all the evidence. (emphasis in original)

M.P.E.P. §2164.05.

See also *In re Alton*, 37 U.S.P.Q.2d 1578, 1582 (Fed. Cir. 1996):

... the examiner's final rejection and Answer contained two errors: ... (2) the summary dismissal of the declaration, without an adequate explanation of why the declaration failed to rebut the Board's prima facie case of inadequate written description.

However, the undersigned noted that in many cases the Examiner had summarily dismissed applicants' declarations, seemingly on the basis of a difference of opinion between the Examiner and the declarants.

Utility of Post-Filing Date References

The undersigned further noted that in response to the enablement rejections, applicants and/or the experts who submitted declarations had cited post-filing date references demonstrating that applicants and others had used the RET assay, as disclosed in the specification, to identify inhibitors of HIV-1 fusion. The undersigned also noted that the Examiner had invariably failed to consider these references on the ground that they had been published after the application filing date. The undersigned quoted the Examiner's April 20, 2004 Office Action in connection with U.S. Serial No. 09/460,216:

Applicants: Virginia M. Litwin et al.
Serial No.: 09/891,062
Filed: June 25, 2001
Page 8

Applicants are reminded that in order to overcome a prima facie case for lack of enablement, applicants must demonstrate that the disclosure was enabled as of the filing of the application. Publications dated after the filing date providing information publicly first disclosed after the filing date generally cannot be used to show what was known at the time of filing. (citations omitted)

The undersigned stated that he fully agreed with this statement but noted that the post-filing date publications had not been used to show what was known at the time of filing. Rather, these publications had been submitted as evidence that the disclosures in the specification as filed are sufficient to enable a person skilled in the art to practice the invention being claimed without undue experimentation, i.e., to demonstrate that the disclosure was enabling as of the filing date. The undersigned noted that several Federal Circuit decisions confirm the utility of post-filing date references for this purpose, for example, *Gould v. Quigg* 3 U.S.P.Q.2d 1302 (Fed. Circ. 1987):

As to the technical article, it is true that a later dated publication cannot supplement an insufficient disclosure in a prior dated application to render it enabling. In this case, the later dated publication was not offered as evidence for this purpose. Rather, it was offered as evidence of the level of ordinary skill in the art at the time of the application and as evidence that the disclosed device would have been operative. ... It was not legal error for the district court to accept the testimony of an expert who had considered a later publication in the formulation of his opinion as to whether the disclosure was enabling as of the time of the filing date of the '540 application. *Gould v. Quigg* 3 U.S.P.Q.2d 1302, 1305.

Rebuttal of Prima Facie Case of Non-Enablement

The undersigned noted that the initial burden is on the Examiner to make a prima facie case of non-enablement. The undersigned stated that applicants did not think the Examiner had made out a prima facie case in the applications to be discussed, but even assuming he had done so, applicants are entitled to rebut such a

Applicants: Virginia M. Litwin et al.
Serial No.: 09/891,062
Filed: June 25, 2001
Page 9

prima facie case. It was noted that the Examiner is then required to respond to applicants' rebuttal with specificity. The undersigned maintained that applicants had rebutted the Examiner's findings of lack of enablement by argument and, in some instances, by filing expert declarations. The undersigned reiterated that, in response, the Examiner had not given due weight to the submitted declarations (citing M.P.E.P. §2164.05; *In re Alton*) and, contrary to *Gould v. Quigg*, had invariably dismissed evidence of enablement based on post-filing date publications.

Grouping of Applications for Discussion

The undersigned stated that U.S. Serial Nos. 09/904,356, 09/460,216, 09/891,062 and 09/412,284 would be grouped together (Group I) for discussion, separate from U.S. Serial No. 10/116,797 (Group II). The undersigned noted that the Group I applications are related in that they involve methods for inhibiting HIV-1 fusion using an agent that binds to the CCR5 coreceptor, which agent is identified by the RET assay, although CCR5 is not referred to by name in U.S. Serial Nos. 09/904,356, 09/891,062 and 09/412,284. The undersigned also stated, however, that differences observed in the inhibition of fusion of macrophage-tropic versus T cell-tropic HIV-1 strains with PM-1 target cells were later discovered by applicants to be due to binding of the inhibitor to CCR5 which is the coreceptor for macrophage-tropic HIV-1 strains.

The undersigned noted that the CCR5 coreceptor is specifically referred to in U.S. Serial No. 09/460,216, and further noted that in U.S. Serial Nos. 09/891,062 and 09/412,284, the agent is a monoclonal antibody. The undersigned noted that the Examiner had rejected the claims in these Group I applications on the grounds of inadequate written description and lack of enablement.

Applicants: Virginia M. Litwin et al.
Serial No.: 09/891,062
Filed: June 25, 2001
Page 10

The undersigned noted that U.S. Serial No. 10/116,797 in Group II was separate from the Group I applications to the extent that it is a later application which discloses specific monoclonal antibodies that bind to CCR5 and inhibit HIV-1 infection. The undersigned also noted that the claimed invention is directed to reducing HIV-1 viral load in an HIV-1 infected subject and that the issues raised in this application are less complex than in the Group I applications. The undersigned stated that amended claims had been drafted in connection with U.S. Serial No. 10/116,797, which were believed to obviate the Examiner's grounds of rejection in the October 6, 2004 Office Action. In this regard, the undersigned noted that draft claims for the Examiner's consideration had been forwarded to him by facsimile and e-mail on December 6, 2004. The Examiner acknowledged that he had received these draft claims.

Discussion of the Subject Application (Serial No. 09/891,062)

The subject application was the third application discussed during the interview following the discussion of U.S. Serial Nos. 09/904,356 and 09/460,216.

The undersigned noted that claims 40-47 are pending in the subject application. The undersigned also noted that claim 40, the sole independent claim, had been amended in applicants' March 24, 2004 Amendment filed in response to the September 24, 2003 Final Office Action, but that the Examiner had stated in May 28, 2004 Advisory Action that the proposed amendments would not be entered. The undersigned further noted that applicants had filed a Request for Continued Examination on August 25, 2004 to enter the March 24, 2004 Amendment.

The undersigned also noted that the subject invention is directed to a method of inhibiting HIV-1 infection of a CD4+ cell which

Applicants: Virginia M. Litwin et al.
Serial No.: 09/891,062
Filed: June 25, 2001
Page 11

comprises contacting the CD4+ cell with an amount of a monoclonal antibody or portion thereof effective to (a) specifically inhibit 67% or greater of fusion of a CD4+ PM-1 cell to a HeLa cell expressing envelope glycoprotein from HIV-1_{M-M}, and (b) inhibit 18% or less of fusion of a CD4+ SUP-T1 cell to a HeLa cell expressing envelope protein from HIV-1_{LAI}, wherein the antibody (i) does not cross-react with HIV-1 envelope glycoprotein or CD4, (ii) reacts with an antigen on the surface of a PM-1 cell, (iii) does not react with an antigen on the surface of a SUP-T1 cell, and (iv) is at least as active as monoclonal antibody PA-7 in inhibiting fusion as recited in (a) above and less active than monoclonal antibody PA-6 in inhibiting fusion as recited in (b) above, so as to thereby inhibit HIV-1 infection of the CD4+ cell. The undersigned further noted that the claims pending in this application are similar to the claims in U.S. Serial No. 09/904,356, except that the agent recited in the present claims which inhibits HIV-1 infection of a CD4+ cell is limited to a monoclonal antibody (MAb).

The Examiner stated that his objection to claim 40 is that it is directed to a method of inhibiting HIV-1 infection of a CD4+ cell by administering a MAb but it is not clear to what the MAb binds. The Examiner asked whether the MAb binds, for example, to CD4.

The undersigned responded that the MAb binds to CCR5 but that this fact was not known at the time of filing. The undersigned stated that what was known was that the MAb was binding to an antigen that is present on the surface of a PM-1 cell but is not present on the surface of a SUP-T1 cell. The undersigned also asserted that the specification enables a person skilled in the art to raise antibodies to a PM-1 cell, then use the RET assay to identify those antibodies which meet the limitations of the claims.

Applicants: Virginia M. Litwin et al.
Serial No.: 09/891,062
Filed: June 25, 2001
Page 12

The undersigned also suggested that claim 40 could be amended to recite "a method of inhibiting macrophage-tropic HIV-1 infection of a CD4+ cell ..." In response, the Examiner stated that such an amendment might be helpful.

The undersigned pointed out that applicants had filed a June 17, 2003 expert declaration by Dr. Ronald C. Kennedy to support their arguments that the specification provided an adequate written description of the claimed invention, and that it was not necessary for one skilled in the art to know the antigenic determinants or structure of an antibody molecule to make monoclonal antibodies that meet the limitations of the claims. The Examiner reviewed Dr. Kennedy's declaration.

The undersigned noted that, as discussed in Dr. Kennedy's declaration (see paragraph 13), the subject specification discloses MAbs PA3, PA5, PA6 and PA7 as examples of MAbs that meet the limitations of the claims. The undersigned also pointed to paragraph 9 of Dr. Kennedy's declaration which confirms that, based on the subject specification, one skilled in the art can readily make monoclonal antibodies having the fusion-inhibiting characteristics recited in the claims.

After reviewing Dr. Kennedy's declaration, the Examiner stated that he would discuss applicants' arguments with his Supervisory Patent Examiner. The Examiner also stated that following this discussion with his supervisor, he would provide guidance to applicants whether the claims are allowable or whether allowance would be dependent upon any further amendment(s).

Conclusion

Applicants respectfully request that the Examiner, in consultation with his Supervisory Patent Examiner, consider

Applicants: Virginia M. Litwin et al.
Serial No.: 09/891,062
Filed: June 25, 2001
Page 13

applicants' remarks in their March 24, 2004 Amendment in light of the discussion summarized above. Applicants maintain that their arguments made in the March 24, 2004 Amendment and hereinabove obviate the grounds of rejection set forth in the September 24, 2003 Office Action.

If a telephone interview would be of assistance in advancing prosecution of the subject application, applicants' undersigned attorney invites the Examiner to telephone him at the number provided below.

No fee is deemed necessary in connection with the filing of this Communication. However, if any fee is required, authorization is hereby given to charge the amount of any such fee to Deposit Account No. 03-3125.

Respectfully submitted,

John P. White
John P. White
Registration No. 28,678
Attorney for Applicants
Cooper & Dunham, LLP
1185 Avenue of the Americas
New York, New York 10036
(212) 278-0400

John P. White 11/4/05

I hereby certify that this correspondence is being transmitted via facsimile on this date to:	
Commissioner for Patents, P.O. Box 1450, Alexandria, VA 22313-1450.	
John P. White Reg. No. 28,678	Date